Published in Antimicrob Agents Chemother on October 01, 1973
In vitro activity of ticarcillin against anaerobic bacteria compared with that of carbenicillin and penicillin. Antimicrob Agents Chemother (1977) 2.71
Pirbenicillin, a new semisynthetic penicillin with broad-spectrum activity. Antimicrob Agents Chemother (1976) 2.12
Study of the effects of ticarcillin on blood coagulation and platelet function. Antimicrob Agents Chemother (1975) 1.49
Ticarcillin in combination with cephalothin or gentamicin as empiric antibiotic therapy in granulocytopenic cancer patients. Antimicrob Agents Chemother (1976) 1.08
Clinical and pharmacological studies of ticarcillin in gram-negative infections. Antimicrob Agents Chemother (1976) 0.95
Amikacin and cephalothin: empiric regimen for granulocytopenic cancer patients. Antimicrob Agents Chemother (1977) 0.95
Empirical antibiotic therapy in the febrile neutropenic cancer patient: clinical efficacy and impact of monotherapy. Antimicrob Agents Chemother (1987) 0.87
Mezlocillin for treatment of infections in cancer patients. Antimicrob Agents Chemother (1980) 0.83
Potential of mezlocillin as empiric single-agent therapy in febrile granulocytopenic cancer patients. Antimicrob Agents Chemother (1980) 0.78
Determination of ticarcillin levels in serum by high-pressure liquid chromatography. Antimicrob Agents Chemother (1985) 0.75
Comparative activity in vitro of ticarcillin, BL-P1654, and carbenicillin. Antimicrob Agents Chemother (1976) 0.75
Choice among penicillins and cephalosporins. Br Med J (1974) 0.75
Infections in cancer patients. Results with gentamicin sulfate therapy. Cancer (1972) 4.47
CAUSES OF DEATH IN ACUTE LEUKEMIA: A TEN-YEAR STUDY OF 414 PATIENTS FROM 1954-1963. JAMA (1965) 4.19
Gram-negative septicemia: a growing threat. Ann Surg (1967) 3.62
Carbenicillin: clinical and laboratory experience with a parenterally administered penicillin for treatment of Pseudomonas infections. Ann Intern Med (1969) 3.62
Clinical pharmacology of ticarcillin (alpha-carboxyl-3-thienylmethyl penicillin, BRL-2288). Antimicrob Agents Chemother (1973) 2.47
Carbenicillin therapy for pseudomonas infections. JAMA (1971) 2.40
In vitro studies of alpha-carboxyl-3-thienylmethyl penicillin, a new semisynthetic penicillin. Appl Microbiol (1971) 2.35
Carbenicillin therapy of gram-negative bacilli infections. Am J Med Sci (1969) 2.25
-carboxy-3-thienylmethylpenicillin (BRL 2288), a new semisynthetic penicillin: in vitro evaluation. Antimicrob Agents Chemother (Bethesda) (1970) 1.95
Antibiotic combinations for infections in neutropenic patients. Evaluaton of carbenicillin plus either cephalothin or kanamycin. Cancer (1972) 1.35
Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med (1966) 7.30
Mezlocillin: in vitro studies of a new broad-spectrum penicillin. Antimicrob Agents Chemother (1977) 7.24
Infections caused by Pseudomonas aeruginosa. Rev Infect Dis (1983) 7.19
Thienamycin: new beta-lactam antibiotic with potent broad-spectrum activity. Antimicrob Agents Chemother (1979) 5.81
In vitro studies of semisynthetic alpha-(substituted-ureido) penicillins. Appl Microbiol (1971) 5.23
Proceedings: Causes of death in cancer patients. Cancer (1974) 4.56
Infections in cancer patients. Results with gentamicin sulfate therapy. Cancer (1972) 4.47
Fluconazole susceptibility testing of Candida albicans: microtiter method that is independent of inoculum size, temperature, and time of reading. Antimicrob Agents Chemother (1991) 4.36
Fungal infections complicating acute leukemia. J Chronic Dis (1966) 4.07
Wild-type p53 binds to the TATA-binding protein and represses transcription. Proc Natl Acad Sci U S A (1992) 4.06
Azlocillin: in vitro studies of a new semisynthetic penicillin. Antimicrob Agents Chemother (1977) 4.00
Prevention of central venous catheter-related infections by using maximal sterile barrier precautions during insertion. Infect Control Hosp Epidemiol (1994) 3.94
Resistance to ticarcillin-potassium clavulanate among clinical isolates of the family Enterobacteriaceae: role of PSE-1 beta-lactamase and high levels of TEM-1 and SHV-1 and problems with false susceptibility in disk diffusion tests. Antimicrob Agents Chemother (1988) 3.92
Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients. Eur J Cancer (1998) 3.81
In vitro activity of carbenicillin against gram-negative bacilli. J Bacteriol (1968) 3.41
Piperacillin: in vitro evaluation. Antimicrob Agents Chemother (1978) 3.21
Emerging fungal pathogens. Eur J Clin Microbiol Infect Dis (1989) 3.14
Zygomycosis in the 1990s in a tertiary-care cancer center. Clin Infect Dis (2000) 2.78
International Conference for the Development of a Consensus on the Management and Prevention of Severe Candidal Infections. Clin Infect Dis (1997) 2.78
Cyclophosphamide (NSC-26271), vincristine (NSC-67574), cytosine arabinoside (NSC-63878), and prednisone (NSC-10023) (COAP) combination chemotherapy for acute leukemia in adults. Cancer Chemother Rep (1972) 2.71
In vitro evaluation of Ro 13-9904. Antimicrob Agents Chemother (1980) 2.67
Invasive aspergillosis in 2002: an update. Eur J Clin Microbiol Infect Dis (2002) 2.63
Blockage by adenovirus E4orf6 of transcriptional activation by the p53 tumor suppressor. Science (1996) 2.56
The nature and control of infections in patients with acute leukemia. Cancer Res (1965) 2.55
Ultrastructural analysis of indwelling vascular catheters: a quantitative relationship between luminal colonization and duration of placement. J Infect Dis (1993) 2.51
Candidiasis in cancer patients. Am J Med (1984) 2.48
Nosocomial infections due to Xanthomonas maltophilia (Pseudomonas maltophilia) in patients with cancer. Rev Infect Dis (1991) 2.47
Clinical pharmacology of ticarcillin (alpha-carboxyl-3-thienylmethyl penicillin, BRL-2288). Antimicrob Agents Chemother (1973) 2.47
PC-904, a new semisynthetic penicillin. Antimicrob Agents Chemother (1978) 2.46
Carbenicillin therapy for pseudomonas infections. JAMA (1971) 2.40
From the Infectious Diseases Society of America. Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. J Infect Dis (1990) 2.39
In vitro studies of alpha-carboxyl-3-thienylmethyl penicillin, a new semisynthetic penicillin. Appl Microbiol (1971) 2.35
Carbenicillin therapy of gram-negative bacilli infections. Am J Med Sci (1969) 2.25
Comparative in vitro study of SQ26,776. Antimicrob Agents Chemother (1982) 2.23
In vitro evaluation of cefoperazone. Antimicrob Agents Chemother (1980) 2.22
Pseudomonas bacteremia. Retrospective analysis of 410 episodes. Arch Intern Med (1985) 2.17
Emerging fungal pathogens in immunocompromised patients: classification, diagnosis, and management. Clin Infect Dis (1993) 2.17
Ciprofloxacin-induced nephrotoxicity in patients with cancer. Arch Intern Med (1993) 2.16
New spectrum of fungal infections in patients with cancer. Rev Infect Dis (1989) 2.16
Trichosporon beigelii infection: a review. Rev Infect Dis (1987) 2.15
1997 guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Infectious Diseases Society of America. Clin Infect Dis (1997) 2.14
Pirbenicillin, a new semisynthetic penicillin with broad-spectrum activity. Antimicrob Agents Chemother (1976) 2.12
Amoxicillin: in vitro and pharmacological studies. Antimicrob Agents Chemother (1972) 2.12
Infections in cancer patients. Cancer Treat Rev (1975) 2.12
Community respiratory virus infections among hospitalized adult bone marrow transplant recipients. Clin Infect Dis (1996) 2.12
Low infection rate and long durability of nontunneled silastic catheters. A safe and cost-effective alternative for long-term venous access. Arch Intern Med (1993) 2.10
Bacteremia caused by Campylobacter-like organisms in two male homosexuals. Ann Intern Med (1984) 2.07
Systemic candidiasis in cancer patients. Am J Med (1984) 2.05
Comparative in vitro study in new cephalosporins. Antimicrob Agents Chemother (1981) 2.04
Comparative in vitro study of teichomycin A2. Antimicrob Agents Chemother (1983) 2.00
Candida krusei fungemia. An escalating serious infection in immunocompromised patients. Arch Intern Med (2000) 1.95
Phase II study of S-1, a novel oral fluorophyrimidine derivative, in patients with metastatic colorectal carcinoma. S-1 Cooperative Colorectal Carcinoma Study Group. Br J Cancer (2000) 1.93
Comparative in vitro activities of teichomycin and other antibiotics against JK diphtheroids. Antimicrob Agents Chemother (1983) 1.93
Determining the site of the primary cancer in patients with skeletal metastasis of unknown origin: a retrospective study. Cancer (1999) 1.92
Klebsiella bacteremia in cancer patients. Am J Med Sci (1973) 1.87
In vitro studies of BB-K8, a new aminoglycoside antibiotic. Antimicrob Agents Chemother (1973) 1.86
A randomized study of carbenicillin plus cefamandole or tobramycin in the treatment of febrile episodes in cancer patients. Am J Med (1979) 1.86
The relationship between the thrombotic and infectious complications of central venous catheters. JAMA (1994) 1.85
Outcomes of bacteremia in patients with cancer and neutropenia: observations from two decades of epidemiological and clinical trials. Clin Infect Dis (1997) 1.84
Treatment of hepatosplenic candidiasis with liposomal-amphotericin B. J Clin Oncol (1987) 1.83
In vitro studies of cefamandole. Antimicrob Agents Chemother (1976) 1.81
Detection of Serratia outbreaks in hospital. Lancet (1976) 1.81
Comparative in vitro activity of cephalosporins. J Antibiot (Tokyo) (1976) 1.79
Oncogenic potential of the adenovirus E4orf6 protein. Proc Natl Acad Sci U S A (1996) 1.78
Infectious complications of indwelling vascular catheters. Clin Infect Dis (1992) 1.77
Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor drug. Clin Cancer Res (1999) 1.76
Paramutagenic Systems in Some South American Races of Corn. Genetics (1965) 1.76
An early phase II study of oral S-1, a newly developed 5-fluorouracil derivative for advanced and recurrent gastrointestinal cancers. The S-1 Gastrointestinal Cancer Study Group. Oncology (1999) 1.75
Serratia sp. infections in cancer patients. Cancer (1970) 1.73
Comparative in vitro study of temocillin (BRL 17421), a new penicillin. Antimicrob Agents Chemother (1982) 1.73
Is a picture worth a thousand medical words? A randomized trial of reporting formats for medical research data. Methods Inf Med (1991) 1.70
Epidemiological studies of Pseudomonas species in patients with leukemia. Am J Med Sci (1970) 1.70
The heart in acute leukemia. A study of 420 autopsy cases. Am J Cardiol (1968) 1.69
Influenza among hospitalized adults with leukemia. Clin Infect Dis (1997) 1.68
Causes of death in adults with acute leukemia. Medicine (Baltimore) (1976) 1.65
Treatment of systemic fungal infections with liposomal amphotericin B. Arch Intern Med (1989) 1.64
Recent experience with Pseudomonas aeruginosa bacteremia in patients with cancer: Retrospective analysis of 245 episodes. Arch Intern Med (2000) 1.62
Characteristics of accelerated disease in chronic myelogenous leukemia. Cancer (1988) 1.62
Clinical pharmacology of sisomicin. Antimicrob Agents Chemother (1975) 1.61
Immunoglobulin on tumor cells and tumor-induced lymphocyte blastogenesis in human acute leukemia. N Engl J Med (1973) 1.57
Antibiotics and prevention of microbial colonization of catheters. Antimicrob Agents Chemother (1995) 1.57
Infection in cancer patients. A continuing association. Am J Med (1986) 1.55
Fungal infection and fever of unknown origin in neutropenic patients. Am J Med (1986) 1.54
Catheter-related infections caused by the Mycobacterium fortuitum complex: 15 cases and review. Rev Infect Dis (1992) 1.54
Mycobacteriosis in patients with malignant disease. Arch Intern Med (1976) 1.54
Therapy-related leukemia and myelodysplastic syndrome: clinical, cytogenetic, and prognostic features. J Clin Oncol (1986) 1.54